Biobeat
Biobeat develops FDA-cleared cuffless blood pressure monitoring wearables and a cloud analytics platform using proprietary PPG sensors, serving US hospitals, cardiology practices, and remote care programs for hypertension diagnosis and management.
- Company typePrivate
- Founded2016
- HeadquartersBoca Raton, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biobeat does
Biobeat is an Israel-headquartered med-tech company founded in 2016 that develops FDA-cleared cuffless remote patient monitoring devices built on proprietary reflective photoplethysmography (PPG) sensors. Its product portfolio centers on a disposable chest patch (BB-613 Chest Monitor) for 24-hour ambulatory blood pressure monitoring (ABPM) and a wrist-worn monitor (BB-613 Wrist Monitor) for long-term continuous vital sign capture, with both form factors streaming 13 vital signs (BP, heart rate, SpO2, respiration rate, HRV, ECG, temperature, cardiac output, and systemic vascular resistance) to a cloud-based analytics platform with EPIC EMR integration. Biobeat holds five FDA 510(k) clearances (K190792, K181006, K212153, K222010, K241066) and CE Mark (CE 2797), and its PPG-to-BP algorithm has been validated against invasive arterial catheter measurements with a correlation of 0.959.
The company's revenue model combines hardware sales of disposable patches and wrist monitors with a recurring cloud platform and analytics subscription that automatically generates clinical reports within 30 seconds of test completion. Go-to-market is primarily a direct enterprise field sales motion targeting US academic medical centers, integrated delivery networks, and specialty cardiology/nephrology/hypertension practices, supplemented by regional distribution partners in the Dominican Republic (Bionex) and Argentina/Chile (Infinity Pharma SA). The platform supports hypertension diagnosis, white-coat and masked hypertension detection, medication titration, nighttime BP pattern analysis, hospital-at-home remote monitoring (via Inbound Health), and wearable cardioverter defibrillator integration (via Kestra Medical Technologies). An ML-powered Early Warning Score predicts patient deterioration up to 30 hours before clinical decline, and a Patient Diary module correlates patient-reported events (medications, meals, sleep, mood) with physiological measurements.
Biobeat is backed by approximately $58 million in disclosed funding, including a $50 million Series B closed on December 30, 2025, led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical Technologies with a $5 million strategic equity investment from Kestra Medical Technologies. The company is led by co-founder and CEO Arik Ben Ishay and Executive Chairman Raymond W. Cohen (former CEO of Axonics, acquired by Boston Scientific for $3.7 billion in 2024). Biobeat operates from Petah Tikva, Israel and Boca Raton, Florida, serving nine named US health systems including University of Miami Health System, Northwell Health, NYU Langone Health, and Mount Sinai Health System.
Biobeat firmographics
Firmographics- Name
- Biobeat
- Legal name
- Biobeat Technologies Ltd.
- Website
- https://bio-beat.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biobeat develops FDA-cleared cuffless blood pressure monitoring wearables and a cloud analytics platform using proprietary PPG sensors, serving US hospitals, cardiology practices, and remote care programs for hypertension diagnosis and management.
- Ownership category
- akta.pro rank
Biobeat industry classification
Industry- Product category
- Remote Patient Monitoring Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Measuring and Controlling Device Manufacturing (334519)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Blood Pressure Monitoring (Cuff & Cuffless) (HLAHACAC)
- akta.pro secondary industries
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF), Blood Pressure Monitors (Smart Cuffs) (CRACAQAB)
Keywords
Where Biobeat is headquartered
LocationHeadquarters
- HQ city
- Boca Raton
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Biobeat business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Sales (Patch and Monitor): Biobeat generates revenue through the sale of its FDA-cleared cuffless ambulatory blood pressure monitoring devices including disposable chest patches and wrist monitors. The company sells directly to healthcare systems and through distribution partners.
- Cloud Platform / Software: The Biobeat platform provides cloud-based data analysis, automatic report generation, and EMR integration services. Data is available within seconds after test completion through a web-based dashboard and directly in institutional EMR systems.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Biobeat product offering
Product offeringCore offering
Biobeat develops and sells FDA-cleared, cuffless ambulatory blood pressure monitoring devices based on proprietary reflective photoplethysmography (PPG) sensor technology. The platform includes a disposable chest patch (BB-613) for 24-hour ABPM and a wrist monitor for long-term continuous monitoring, capturing 13 vital signs (BP, heart rate, SpO2, respiration rate, HRV, ECG, temperature, cardiac output, and systemic vascular resistance). Data is transmitted wirelessly to a cloud platform that generates automated clinical reports within seconds and integrates directly with EMR systems like EPIC.
Product overview
Biobeat offers a unified medical-grade wearable monitoring platform consisting of two primary device form factors—the disposable BB-613 chest patch for short-term 24-hour ambulatory blood pressure monitoring and the BB-613 wrist monitor for long-term continuous monitoring—plus a cloud-based analytics platform that processes vital signs data using AI algorithms. The Biobeat Platform integrates with EPIC EMR systems and provides automated report generation, Early Warning Scores, and the Patient Diary add-on module for enhanced clinical insights. All devices utilize proprietary reflective photoplethysmography (PPG) sensing technology to enable FDA-cleared cuffless blood pressure measurement.
Differentiator
Problem solved
Functional benefit
Brands
- Biobeat BPM System: FDA-cleared, patch-worn, cuff-less 24-hour ambulatory blood pressure monitoring system for hypertension diagnosis and management
- Biobeat Patient Diary
- Biobeat Cloud Platform
Products and services
- Biobeat Chest Monitor (BB-613) Disposable chest-worn patch sensor that provides continuous 24-hour ambulatory blood pressure monitoring using cuffless PPG technology. Automatically captures 13 vital signs and transmits data wirelessly to the cloud platform for AI-aided analysis. Designed for hospital systems, cardiologists, and hypertension specialists diagnosing hypertension and assessing medication effectiveness.
- Biobeat Wrist Monitor (BB-613) Wrist-worn device resembling a smartwatch for long-term continuous vital sign monitoring. Measures 13 vital signs continuously, wirelessly, and in real time using proprietary PPG sensor technology.
- ABPM Kit (Ambulatory Blood Pressure Monitoring Kit) Complete kit for 24-hour ambulatory blood pressure monitoring consisting of the chest-worn sensor, connectivity components, and access to the Biobeat web platform for report generation and analysis. Sold to healthcare providers and health systems for clinical hypertension diagnosis.
- Biobeat Cloud Platform (Web Application) Cloud-based data analysis and reporting platform that receives, processes, and analyzes physiological data collected from Biobeat devices. Provides dashboards with trends, PDF reports, automated report generation within seconds, AI/ML Early Warning Score, and direct EMR integration (e.g., EPIC).
Quantifiable outcome
- Correlation of 0.959 with invasive arterial catheter measurements in heart failure patients (JACC Journals: Advances study)
- +2 more outcomes
Companies that use Biobeat
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
Biobeat technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature6 records
Biobeat partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major, minor and core.
- Kestra Medical TechnologiesmajorStrategic collaboration including exclusive license and co-development arrangement plus $5 million equity investment in Biobeat's Series B. Kestra intends to integrate Biobeat's cuffless blood pressure monitoring technology into its ASSURE Wearable Cardioverter Defibrillator (WCD) system. Clinical data shows 72% of WCD patients are hypertensive, highlighting the relevance of this integration.
- BionexminorDistribution agreement for Dominican Republic market. Through this partnership, Biobeat's 24-hour blood pressure monitoring solution (BPM) is made available to healthcare providers across the country.
- Infinity Pharma SAminorDistribution agreement for Argentina and Chile markets. Partnership brings Biobeat's innovative solutions to healthcare providers in South America, enabling clinicians to gain accurate insights into patients' blood pressure patterns for earlier detection of irregularities.
- Inbound HealthcoreStrategic partnership to enhance and expand advanced care at home capabilities. Integration of Biobeat's continuous monitoring wearables into Inbound Health's solution enables care for more complex patients at home with improved patient outcomes through continuous monitoring and early detection of deterioration.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Biobeat competitors and assessment
Company assessmentDirect peers
- Aktiia: Swiss health-tech company developing cuffless blood pressure monitoring using optical sensors and a wrist-worn device. Most direct head-to-head competitor to Biobeat in the FDA-cleared cuffless BP category.
- iRhythm Technologies: Public digital health company behind the Zio long-term cardiac monitoring patch, sold to health systems with cloud-based reporting. Closely comparable business model: disposable wearable patch, AI-driven reports, and enterprise hospital sales motion.
- AliveCor: Maker of KardiaMobile ECG devices and cloud-based cardiac analytics, sold direct to clinicians and consumers. Comparable as a connected cardiac/vital-sign wearable with FDA-cleared algorithms and a SaaS-style reporting platform.
- Withings: Consumer health hardware company with FDA-cleared BPM Core and connected blood pressure monitors integrated into a health cloud platform. Comparable as a smart, connected BP and vital-sign device maker with both consumer and clinical positioning.
- VitalConnect: Maker of the VitalPatch wearable biosensor for continuous multi-parameter vital sign monitoring in hospital and RPM settings. Comparable as an adhesive-patch, multi-vital-sign continuous monitor with cloud analytics sold to hospital systems.
Broad incumbents
- Omron Healthcare: Global leader in traditional blood pressure monitors with a growing connected/smart BP portfolio and RPM services. Comparable as the dominant incumbent in clinical BP measurement that Biobeat is disrupting with a cuffless alternative.
- Preventice Solutions (Boston Scientific): Acquired by Boston Scientific in 2022, Preventice offers BodyGuardian remote cardiac monitoring patches and cloud reporting. Comparable as a large-scale wearable cardiac/RPM patch platform with hospital sales force.
- Philips (BioTelemetry / RPM): Through its BioTelemetry acquisition, Philips operates one of the largest RPM and ambulatory cardiac monitoring service businesses. Comparable as an enterprise-scale RPM provider with hospital and physician channels that Biobeat sells into.
- GE HealthCare: Major medical device and digital health incumbent with bedside and ambulatory patient monitoring products, including the MUSE/AICU ecosystem and growing RPM portfolio. Comparable as a broad incumbent that hospital systems may bundle Biobeat's cuffless ABPM alongside.
Emerging players
- Apple (Health / Watch BP): Apple Watch has explored cuffless BP trend notifications and integrates deeply with health systems via HealthKit. Comparable as a consumer wearable platform whose regulatory progress in cuffless BP could pressure incumbent and emerging players like Biobeat.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Biobeat social profiles
Digital presenceBiobeat compliance and trust
Trust signalCompliance2 records
Biobeat financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biobeat leadership team
Management profileNumber of profiles
Profiles9 records
Biobeat funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biobeat M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biobeat
What does Biobeat do?
Biobeat develops and sells FDA-cleared, cuffless ambulatory blood pressure monitoring devices based on proprietary reflective photoplethysmography (PPG) sensor technology. The platform includes a disposable chest patch (BB-613) for 24-hour ABPM and a wrist monitor for long-term continuous monitoring, capturing 13 vital signs (BP, heart rate, SpO2, respiration rate, HRV, ECG, temperature, cardiac output, and systemic vascular resistance). Data is transmitted wirelessly to a cloud platform that generates automated clinical reports within seconds and integrates directly with EMR systems like EPIC.
Is Biobeat a public or private company?
Biobeat is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biobeat founded?
Biobeat was founded in 2016. It employs 11 to 50 people.
Where is Biobeat based?
Biobeat is headquartered in Boca Raton, United States, in the North America region.
How does Biobeat make money?
Two revenue lines are on record. Medical Device Sales (Patch and Monitor) is the primary driver. The others are cloud Platform / Software.
Who are Biobeat's main competitors?
Direct peers on record are Aktiia, iRhythm Technologies, AliveCor, Withings and VitalConnect. Broad incumbents are Omron Healthcare, Preventice Solutions (Boston Scientific), Philips (BioTelemetry / RPM) and GE HealthCare. Apple (Health / Watch BP) is listed as an emerging player.
Does Biobeat have an API?
No public API is recorded for Biobeat.
What industry is Biobeat in?
Biobeat's product category is Remote Patient Monitoring Medical Devices. Its primary akta.pro industry code is HLAHACAC, Blood Pressure Monitoring (Cuff & Cuffless), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.